Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of Ruxolitinib When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

Inclusion Criteria:

• Subjects must have psoriatic lesions measuring protocol specific BSA

Exclusion Criteria:

• Lesions solely involving the palms of the hands, the soles of the feet, the intertriginious areas, the scalp or the face
• Pustular psoriasis or erythroderma